BofA analyst Michael Ryskin raised the firm’s price target on Illumina to $230 from $210 and keeps a Neutral rating on the shares, stating there were "no big surprises" as the company reported Q4 results in-line with preliminary results released on January 10. The Q1 guidance was weaker than expected, but Illumina reiterated its FY23 guidance, noted the firm, which still projects FY23 adjusted EPS of $1.30, but raised its estimates for FY24-25. BofA adds that it thinks shares will remain range-bound as the Grail, NovaSeqX, and FY23 narratives play out.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ILMN:
- Illumina price target lowered to $150 from $160 at Barclays
- Illumina sees FY23 adjusted EPS $1.25-$1.50, consensus $1.98
- Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022
- Illumina reports Q4 adjusted EPS 14c, consensus 10c
- Illumina options imply 6.4% move in share price post-earnings